Figure 3
From: ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients
Impact of ALK variants on the overall survival of ALK inhibitor(s) (a) and platinum plus pemetrexed (b) treatment.
Figure 3 | Scientific Reports
